radiosensitivity

MK-8033 is a new and selective dual ATP competitive c-Met Ron inhibitor (IC50: 1 nM Wt c-Met).

GSK484 hydrochloride (GTPL8577) is a reversible peptidyl-arginine deiminase 4 (PAD4) inhibitor. It binds to PAD4 with high affinity, with IC50 of 250 and 50 nM in the presence and absence of 2 mM calcium, respectively. GSK484 promotes the radiosensitivity of colorectal cancer (CRC) and inhibits NET formation in vitro and in vivo.

E7016 (GPI 21016) is an orally available PARP inhibitor that inhibits DNA repair and enhances tumor cell radiosensitivity both in vitro and in vivo.

SENP1-IN-4, a distinct inhibitor of the deSUMOylation protease 1 (SENP1), is designed to enhance tumor radiosensitivity.

Sodium glycididazole (Sodium glycididazole), a radiosensitizer, enhances the radiosensitivity of nasopharyngeal carcinoma cells by increasing DNA damage and augmenting apoptosis (apoptosis) in these cells.

ART899, a derivative of ART558, is a potent and specific conformational inhibitor of DNA polymerase θ (Polθ). It specifically inhibits the MMEJ activity of Polθ with an IC50 of 180 nM. Additionally, ART899 selectively enhances the radiosensitivity of tumor cells and possesses a strong independent antitumor effect on cancer cells.

SENP1-IN-3 is a distinct inhibitor of the deSUMOylation protease 1 (SENP1), designed to enhance tumor radiosensitivity.

SENP1-IN-1 is a distinct inhibitor of the deSUMOylation protease 1 (SENP1), designed to enhance tumor radiosensitivity.

SENP1-IN-2, a distinct inhibitor of the deSUMOylation protease 1 (SENP1), is designed to enhance tumor radiosensitivity.

1-Methylxanthine is a caffeine derivative. 1-Methylxanthine is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP). 1-Methylxanthine enhances the radiosensitivity of tumor cells.

TMU 35435 is an inhibitor of histone deacetylases (HDAC). It enhances radiosensitivity by inducing the accumulation of misfolded proteins and autophagy (autophagy) in TNBC, and inhibits the NHEJ pathway through ubiquitination of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs).